Royalty Pharma plc
RPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $11,377 | $12,573 | $17,308 | $16,530 |
| - Cash | $929 | $477 | $1,711 | $1,541 |
| + Debt | $7,612 | $6,135 | $7,116 | $7,096 |
| Enterprise Value | $18,060 | $18,231 | $22,714 | $22,085 |
| Revenue | $2,264 | $2,355 | $2,237 | $2,289 |
| % Growth | -3.9% | 5.2% | -2.3% | – |
| Gross Profit | $2,264 | $2,355 | $2,237 | $2,289 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $1,556 | $1,887 | $424 | $1,430 |
| % Margin | 68.8% | 80.2% | 18.9% | 62.5% |
| Net Income | $859 | $1,135 | $43 | $620 |
| % Margin | 37.9% | 48.2% | 1.9% | 27.1% |
| EPS Diluted | 1.91 | 2.53 | 0.1 | 1.49 |
| % Growth | -24.5% | 2,430% | -93.3% | – |
| Operating Cash Flow | $2,769 | $2,988 | $2,144 | $2,018 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $2,769 | $2,988 | $2,144 | $2,018 |